A

ABL Bio Inc
KOSDAQ:298380

Watchlist Manager
ABL Bio Inc
KOSDAQ:298380
Watchlist
Price: 34 450 KRW 2.23% Market Closed
Market Cap: 1.7T KRW

ABL Bio Inc
Operating Expenses

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

ABL Bio Inc
Operating Expenses Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Operating Expenses CAGR 3Y CAGR 5Y CAGR 10Y
A
ABL Bio Inc
KOSDAQ:298380
Operating Expenses
-â‚©92.8B
CAGR 3-Years
-17%
CAGR 5-Years
-16%
CAGR 10-Years
N/A
Celltrion Inc
KRX:068270
Operating Expenses
-â‚©1.2T
CAGR 3-Years
-51%
CAGR 5-Years
-36%
CAGR 10-Years
-23%
SK Bioscience Co Ltd
KRX:302440
Operating Expenses
-â‚©169.4B
CAGR 3-Years
-21%
CAGR 5-Years
-25%
CAGR 10-Years
N/A
H
Hugel Inc
KOSDAQ:145020
Operating Expenses
-â‚©120.9B
CAGR 3-Years
-14%
CAGR 5-Years
-10%
CAGR 10-Years
N/A
P
PharmaResearch Co Ltd
KOSDAQ:214450
Operating Expenses
-â‚©125.2B
CAGR 3-Years
-31%
CAGR 5-Years
-32%
CAGR 10-Years
-34%
Alteogen Inc
KOSDAQ:196170
Operating Expenses
-â‚©38.7B
CAGR 3-Years
-23%
CAGR 5-Years
-24%
CAGR 10-Years
-28%

ABL Bio Inc
Glance View

Market Cap
1.7T KRW
Industry
Biotechnology

ABL Bio, Inc. engages in the development of therapeutic drugs for immuno-oncology and neurodegenerative diseases. The company is headquartered in Seongnam, Gyeonggi-Do. The company went IPO on 2018-12-19. The major products include anti-angiogenesis antibodies anti-tumor targeting antibodies, T cell engager bispecific antibodies (TCEs), dual immune cell targeting bispecific antibodies (DICs), novel immune cell targeting antibodies (NICs), brain disease dual antibodies, antibody-drug conjugates (ADCs) , among others.

Intrinsic Value
9 630.52 KRW
Overvaluation 72%
Intrinsic Value
Price
A

See Also

What is ABL Bio Inc's Operating Expenses?
Operating Expenses
-92.8B KRW

Based on the financial report for Dec 31, 2024, ABL Bio Inc's Operating Expenses amounts to -92.8B KRW.

What is ABL Bio Inc's Operating Expenses growth rate?
Operating Expenses CAGR 5Y
-16%

Over the last year, the Operating Expenses growth was -36%. The average annual Operating Expenses growth rates for ABL Bio Inc have been -17% over the past three years , -16% over the past five years .

Back to Top